The biosimilar insulin landscape: Current developments

Postgraduate Medicine

Volumn 126, Issue 6, 2014, Pages 81-92

  Lavalle González, Fernando J ^a   Khatami, Hootan ^b  

^a UNIVERSIDAD AUTÓNOMA DE NUEVO LEÓN   (Mexico)

^b SANOFI   (France)

Author keywords

Basal; Biologic; Biologic drug; Biosimilar; Diabetes; Insulin

Indexed keywords

BIOSIMILAR AGENT; HEMOGLOBIN A1C; INSULIN; RECOMBINANT HUMAN INSULIN; ANTIDIABETIC AGENT; LONG ACTING INSULIN;

ARTICLE; BIOEQUIVALENCE; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS; ESCHERICHIA COLI; EUROPEAN MEDICINES AGENCY; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HUMAN; HYPERINSULINEMIC-EUGLYCEMIC CLAMP TECHNIQUE; HYPOGLYCEMIA; IMMUNOGENICITY; INSULIN INJECTION PEN; INSULIN SENSITIVITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SACCHAROMYCES CEREVISIAE; WORLD HEALTH ORGANIZATION; DRUG DEVELOPMENT; DRUG LEGISLATION;

BIOSIMILAR PHARMACEUTICALS; DRUG DISCOVERY; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; LEGISLATION, DRUG;

EID: 84922391708     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2014.10.2823     Document Type: Article

References (74)

1. Guariguata L, Whiting DR, Hambleton I, Beagley J, Linnenkamp U, Shaw JE. Global estimates of diabetes prevalence for 2013 and projections for 2035. Diabetes Res Clin Pract. 2014;103(2):137–149.
2. Beagley J, Guariguata L, Weil C, Motala AA. Global estimates of undiagnosed diabetes in adults. Diabetes Res Clin Pract. 2014; 103(2):150–160.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.
4. Unwin N, Setel P, Rashid S, et al. Noncommunicable diseases in sub- Saharan Africa: where do they feature in the health research agenda? Bull World Health Organ. 2001;79(10):947–953.
5. Aje TO, Miller M. Cardiovascular disease: a global problem extending into the developing world. World J Cardiol. 2009;1(1):3–10.
6. Ringborg A, Cropet C, Jönsson B, Gagliardino JJ, Ramachandran A, Lindgren P. Resource use associated with type 2 diabetes in Asia, Latin America, the Middle East and Africa: results from the International Diabetes Management Practices Study (IDMPS). Int J Clin Pract. 2009;63(7):997–1007.
7. US Department of Health and Human Services. US Food and Drug Administration (FDA). What are Generic Drugs? http://www.fda.gov/Drugs/ResourcesForYou/Consumers/BuyingUsingMedicineSafely/UnderstandingGenericDrugs/ucm144456.htm. Accessed July 7, 2014.
8. US Department of Health and Human Services. US Food and Drug Administration (FDA). Information for Consumers (Biosimilars). http://www.fda.gov/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ ApprovalApplications/TherapeuticBiologicApplications/ Biosimilars/ucm241718.htm. Accessed July 7, 2014.
9. ® to become most prescribed daily G-CSF in Europe. July, 2013. http://www.sandoz.com/media_center/press_releases_news/global_news/zarzio_reg_overtakes_neupogen_reg_and_granocyte_reg_to_become_most_prescribed_ daily_g-csf_in_europe_.shtml. Accessed July 7, 2014.
10. Haustein R, de Millas C, Höer A, Häussler B. Saving money in the European healthcare systems with biosimilars. Generics and Biosimilars Initiative Journal (GaBI Journal). 2012;1(3–4):120–126.
11. Rotenstein LS, Ran N, Shivers JP, Yarchoan M, Close KL. Opportunities and challenges for biosimilars: what’s on the horizon in the global insulin market? Clin Diabetes. 2012;30(4):138–150.
12. Gough S. Biosimilar insulins: opportunities and challenges. Pract Diabet. 2013;30(4):146a–147a.
13. Heinemann L. Biosimilar insulins. Expert Opin Biol Ther. 2012; 12(8):1009–1016.
14. Boven K, Stryker S, Knight J, et al. The increased incidence of pure red cell aplasia with an Eprex formulation in uncoated rubber stopper syringes. Kidney Int. 2005;67(6):2346–2353.
15. World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs), October 2009. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_ WEB_22 APRIL2010.pdf. Accessed July 7, 2014.
16. European Medicines Agency. Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues. April 2014. http:// www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/ 2014/04/WC500165988.pdf. Accessed July 7, 2014.
17. US Department of Health and Human Services. US Food and Drug Administration (FDA). Guidance for Industry: Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. http://www.fda. gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM291128.pdf. Accessed July 7, 2014.
18. U.S. Department of Health and Human Services. U.S. Food and Drug Administration (FDA). Guidance for Industry: Quality Considerations in Demonstrating Biosimilarity to a Reference Protein Product. http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM291134.pdf. Accessed July 7, 2014.
19. Tam CS, Xie W, Johnson WD, Cefalu WT, Redman LM, Ravussin E. Defining insulin resistance from hyperinsulinemic-euglycemic clamps. Diabetes Care. 2012;35(7):1605–1610.
20. Reddy S, Balamuralidhara V, Pramod Kumar TM, Teja CH, Reddy S. Regulatory strategies for biosimilars in regulated and emerging markets. Pharma Times. 2013;45(1):11–14. http://www.pharmatimes.com/ Magazine.aspx.
21. Purcell RT, Lockey RF. Immunologic responses to therapeutic biologic agents. J Investig Allergol Clin Immunol. 2008;18(5): 335–342.
22. World Health Organization. 56th Consultation on International Nonproprietary Names for Pharmaceutical Substances Geneva, April 2013. http://www.who.int/medicines/services/inn/56th_Executive_Summary. pdf. Accessed July 7, 2014.
23. French Social Security Bill 2014. LAW No. 2013–1203 of 23 December 2013 financing of social security for 2014 (1); Part Four: Provisions Relating to Expenses for the Year 2014; Section 1: Provisions for health insurance expenditure; Article 47. http://www.legifrance.gouv.fr/affichTexteArticle.do;jsessionidtpdjo06v_3?cidTextedateTexte. Accessed July 7, 2014.
24. Heinemann L, Hompesch M. Biosimilar insulins: how similar is similar? J Diabetes Sci Technol. 2011;5(3):741–754.
25. Owens DR, Landgraf W, Schmidt A, Bretzel RG, Kuhlmann MK. The emergence of biosimilar insulin preparations–a cause for concern? Diabetes Technol Ther. 2012;14(11):989–996.
26. Krämer I, Sauer T. The new world of biosimilars: what diabetologists need to know about biosimilar insulins. Br J Diabetes Vasc Dis. 2010;10(4):163–171.
27. ClinicalTrials.gov. Comparative glucose clamp study of Wockhardt’s recombinant insulin analog glargine (Glaritus) with Lantus in T1DM. http://clinicaltrial.gov/ct2/show/study/NCT01357603. Accessed July 7, 2014.
28. ClinicalTrials.gov. Immunogenicity safety study of Wockhardt’s recombinant insulin analogue in type 1 diabetic patients. http://clinicaltrial. gov/ct2/show/record/NCT01352663. Accessed July 7, 2014.
29. ®) given along with meal time bolus of rapid acting insulin (Lispro) in type 1 diabetic patients [CTRI/2011/11/002173]. http://ctri.nic.in/Clinicaltrials/showallp.php?mid13703&EncHid&userNameglaritus. Accessed July 7, 2014.
30. Biocon. Biocon announces positive results from its phase 1 comparative PK-PD study with biosimilar insulin glargine, July 2012. http://www.biocon.com/biocon_press_release_details.asp?subLinknews&;Fileid443. Accessed July 7, 2014.
31. ® in producing glycemic control in patients with type 1 diabetes mellitus on multiple daily insulin regimens. Int J Diabetes Dev Ctries. 2011;31(1):26–31.
32. Cheng SW, Lu JM, Pang CY. Studies of pharmacokinetic, pharmacodynamic properties and bioequivalence of recombinant insulin glargine injection in healthy man. Chin J Diabetes. 2010;18(8).
33. Zhu LQ, Gu QK, Zhang Y. A study on the control of fasting and postprandial hyperglycemia by glargine insulin combined with oral hypoglycemic agent. Chin J Diabetes. 2009;17(9).
34. ClinicalTrials.gov. A study to compare LY2963016 to Lantus after a single dose to subjects with type 1 diabetes mellitus. http://clinicaltrial. gov/ct2/show/NCT01600950. Accessed July 7, 2014.
35. ®, in subjects with type i diabetes mellitus (T1DM) [abstract 891–P]. Diabetes. 2014;63(suppl 1): A228.
36. ClinicalTrials.gov. A study of LY2963016 in healthy participants. http://clinicaltrial.gov/ct2/show/NCT01634165. Accessed July 7, 2014.
37. ® after single dose administration to healthy participants. http:// clinicaltrial.gov/ct2/show/NCT01688635. Accessed July 7, 2014.
38. ClinicalTrials.gov. A comparison of LY2963016 to a basal insulin after a single dose in healthy subjects. http://clinicaltrial.gov/ct2/show/ NCT01374178. Accessed July 7, 2014.
39. ClinicalTrials.gov. A study to compare the pharmacokinetics and pharmacodynamics of LY2963016 to Lantus in healthy subjects. http:// clinicaltrial.gov/ct2/show/NCT01476345. Accessed July 7, 2014.
40. ClinicalTrials.gov. A study in adults with type 1 diabetes (ELEMENT 1). http://clinicaltrial.gov/ct2/show/NCT01421147. Accessed July 7, 2014.
41. ® insulin glargine in patients with T1DM: the ELEMENT 1study [abstract 69-OR]. Diabetes. 2014;63(Suppl 1):A19.
42. ® insulin glargine in patients with T1DM or T2DM [abstract 70-OR]. Diabetes. 2014;63(Suppl 1):A19.
43. ClinicalTrials.gov. A study in adults with type 2 diabetes (ELEMENT 2). http://clinicaltrial.gov/ct2/show/NCT01421459. Accessed July 7, 2014.
44. ® insulin glargine in patients with T2DM: The ELEMENT 2 study [abstract 64-OR]. Diabetes. 2014;63(Suppl 1):A17.
45. ClinicalTrials.gov. A study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of MK-1293 compared with a basal insulin in participants with type 1 diabetes (MK-1293–005). http:// clinicaltrials.gov/show/NCT02059174. Accessed July 7, 2014.
46. ClinicalTrials.gov. A study of the safety and efficacy of MK-1293 compared to Lantus™ in participants with type 1 diabetes mellitus (T1DM) (MK-1293–003). http://clinicaltrials.gov/show/NCT02059161. Accessed July 7, 2014.
47. ClinicalTrials.gov. The safety and efficacy of MK-1293 versus Lantus™ in participants with type 2 diabetes mellitus (MK-1293–006). http:// clinicaltrials.gov/show/NCT02059187. Accessed July 7, 2014.
48. ClinicalTrials.gov. Comparative glucose clamp study of Wockhardt’s human isophane insulin with Novolin N, in healthy subjects. http:// clinicaltrials.gov/show/NCT00772265. Accessed July 7, 2014.
49. ClinicalTrials.gov. Comparative glucose clamp study of Wockhardt’s insulin human regular for injection and Actrapid, in type 1 diabetics. http://clinicaltrials.gov/show/NCT00752180. Accessed July 7, 2014.
50. ClinicalTrials.gov. Comparative glucose clamp study of Wockhardt’s insulin human regular for injection and Actrapid, in healthy subjects. http://clinicaltrials.gov/show/NCT00719108. Accessed July 7, 2014.
51. ClinicalTrials.gov. Comparative glucose clamp study of Wockhardt’s insulin human regular for injection and Novolin R, in healthy subjects. http://clinicaltrials.gov/show/NCT00596063. Accessed July 7, 2014.
52. ClinicalTrials.gov. Immunosafety study of recombinant human insulins in type 1 diabetics. http://clinicaltrials.gov/ct2/show/NCT01308437. Accessed July 7, 2014.
53. Segal D, Tupy D, Distiller L. The Biosulin equivalence in standard therapy (BEST) study – a multicentre, open-label, non-randomised, interventional, observational study in subjects using Biosulin 30/70 for the treatment of insulin-dependent type 1 and type 2 diabetes mellitus. S Afr Med J. 2013;103(7):458–460.
54. Wockhardt. Search Products. http://www.wockhardt.com/products/ search-products.aspx. Accessed July 7, 2014.
55. Friedrichs A, Bohnet J, Korger V, Adler S, Schubert-Zsilavecz M, Abdel-Tawab M. Dose accuracy and injection force of different insulin glargine pens. J Diabetes Sci Technol. 2013;7(5):1346–1353.
56. Biocon. Biocon enhances partnership with Mylan through strategic collaboration for insulin products…, February 2013. http://www.biocon.com/biocon_press_release_details.asp?subLinknews&Fileid467. Accessed July 7, 2014.
57. Landgraf W, Schmidt A, Schäfer E, Schmeier E, Jochum M. Insulin glargine by-product profiles: a fingerprint of the biotechnological production process. http://www.codhy.com/LA/2012/Uploads/assets/ poster%20board%2028.pdf. Accessed July 7, 2014.
58. European Medicines Agency. Summary of opinion (initial authorisation). Abasria (insulin glargine), June 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/ human/002835/WC500169353.pdf. Accessed July 7, 2014.
59. Lilly. Eli Lilly and Company and Boehringer Ingelheim announce new drug application filing in the U.S. for new insulin glargine product, December 2013. https://investor.lilly.com/releasedetail. cfm?releaseid 815459. Accessed July 7, 2014.
60. ®, in healthy subjects at two dose levels [abtract 890-P]. Diabetes. 2014;63(suppl 1):A227.
61. ® insulin glargine in healthy subjects [abstract 889-P]. Diabetes. 2014;63(suppl 1): A227.
62. ® compared with other disposable insulin pen devices at constant volume flow rates. J Diabetes Sci Technol. 2011;5(1):150–155.
63. Aronson R, Gibney MA, Oza K, Bérubé J, Kassler-Taub K, Hirsch L. Insulin pen needles: effects of extra-thin wall needle technology on preference, confidence, and other patient ratings. Clin Ther. 2013;35(7):923–933.
64. Samsung Bioepis. Samsung Bioepis and Merck enter worldwide collaboration agreement to develop and commercialize biosimilar insulin glargine candidate for diabetes, February 2014. http://www.samsungbioepis. com/newsroom1/newsroom_1.html. Accessed July 7, 2014.
65. Johnson IS. Human insulin from recombinant DNA technology. Science. 1983;219(4585):632–637.
66. Biocon. Biocon announces positive results from its global phase 3 study with recombinant human insulin, October 2012. http://www.biocon.com/biocon_press_release_details.asp?subLinknews&Fileid457. Accessed July 7, 2014.
67. European Medicines Agency. Withdrawal Assessment Report for Insulin Human Rapid Marvel, February 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_ report/2010/01/WC500067086.pdf. Accessed July 7, 2014.
68. European Medicines Agency. Withdrawal Assessment Report for Insulin Human Long Marvel, February 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_ report/2010/01/WC500067170.pdf. Accessed July 7, 2014.
69. European Medicines Agency. Withdrawal Assessment Report for Insulin Human 30/70 Mix Marvel, February 2008. http://www.ema.europa.eu/docs/en_GB/document_library/Application_withdrawal_assessment_ report/2010/01/WC500067169.pdf. Accessed July 7, 2014.
70. Kuhlmann M, Marre M. Lessons learned from biosimilar epoetins and insulins. Br J Diabetes Vasc Dis. 2010;10(2):90–97.
71. Sanofi. IR Thematic Call on Diabetes. San Francisco – June 16th, 2014. http://en.sanofi.com/Images/36711_IRCall_2014_ADA_FINAL.pdf. Accessed July 7, 2014.
72. Kannan V, Narayanaswamy P, Gadamsetty D, Hazra P, Khedkar A, Iyer H. A tandem mass spectrometric approach to the identification of O-glycosylated glargine glycoforms in active pharmaceutical ingredient expressed in Pichia pastoris. Rapid Commun Mass Spectrom. 2009;23(7):1035–1042.
73. Lee JF, Litten JB, Grampp G. Comparability and biosimilarity: considerations for the healthcare provider. Curr Med Res Opin. 2012;28(6):1053–1058.
74. Miletich J, Eich G, Grampp G, Mounho B. Biosimilars 2.0: guiding principles for a global “patients first” standard. MAbs. 2011;3(3):318–325.